Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

KALV KalVista Pharmaceuticals, Inc. Common Stock
$16.08 0.12% +0.02
Notify me if price changes either direction
Interactive Brokers Logotype

Buy KALV stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 820.4M
Enterprise value 793.8M
Trailing PE -4.3829269202421
Forward PE -11.133367
PEG Ratio -3.9884634974203
Enterprise to EBITDA -3.933
Enterprise to revenue 556.653
Price to book MRQ 48.30357
Price to sales TTM 575.29193

Financials

Fiscal Year Ends 2025-04-30
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 1.4M
EBITDA -201820000
Diluted EPS TTM -3.93
Total Cash (MRQ) 309.2M
Current ratio (MRQ) 5.365
Operating Cash Flow (TTM) -167188992

KALV trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent KALV News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.